Bessemer Group
MRVI icon

Bessemer Group’s Maravai LifeSciences MRVI Stock Holding History

Bessemer Group’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3K Hold
943
– – ﹤0.01% 2323
2025
Q4 		$3K Buy
+943
New +$3.17K ﹤0.01% 2360
2025
Q1 		– Sell
-460
Closed -$3K – 2627
2024
Q4 		$3K Sell
460
-155
-25% -$997 ﹤0.01% 2138
2024
Q3 		$5K Buy
+615
New +$5.32K ﹤0.01% 1935
2023
Q2 		– Sell
-24
Closed – – 2315
2023
Q1 		$0 Hold
24
– – ﹤0.01% 2004
2022
Q4 		$0 Sell
24
-27,507
-100% -$433K ﹤0.01% 2062
2022
Q3 		$703K Sell
27,531
-3,298
-11% -$82.8K ﹤0.01% 650
2022
Q2 		$876K Hold
30,829
– – ﹤0.01% 592
2022
Q1 		$1.09M Sell
30,829
-1,562
-5% -$52.4K ﹤0.01% 460
2021
Q4 		$1.36M Buy
32,391
+12,169
+60% +$493K ﹤0.01% 410
2021
Q3 		$992K Buy
20,222
+10,248
+103% +$500K ﹤0.01% 413
2021
Q2 		$416K Buy
9,974
+2,328
+30% +$90.2K ﹤0.01% 618
2021
Q1 		$272K Buy
+7,646
New +$253K ﹤0.01% 692

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bessemer Group's MRVI Position: Q1 2026 in Review

Bessemer Group held its Maravai LifeSciences (MRVI) position steady in Q1 2026 at 943 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2323.

Bessemer Group first reported a position in MRVI in Q1 2021 and has held it in 13 quarters since. The position peaked at $1.36M in Q4 2021. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Bessemer Group held 943 shares of Maravai LifeSciences worth $3K as of Q1 2026.
  • Bessemer Group left its Maravai LifeSciences share count unchanged in Q1 2026.
  • Maravai LifeSciences made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2323 holding.
  • Bessemer Group first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 13 quarters since.
  • Bessemer Group's Maravai LifeSciences position peaked at $1.36M in Q4 2021.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.